Compare ETB & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Eaton Vance Tax-Managed Buy-Write Income Fund Eaton Vance Tax-Managed Buy-Write Income Fund of Beneficial Interest
Current Price
| Metric | ETB | TRDA |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 454.4M | 481.6M |
| IPO Year | 2004 | 2021 |
| Metric | ETB | TRDA |
|---|---|---|
| Price | $14.82 | $11.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 43.5K | ★ 185.8K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $25,421,000.00 |
| Revenue This Year | N/A | $39.97 |
| Revenue Next Year | N/A | $53.29 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.03 | $4.93 |
| 52 Week High | $15.60 | $13.99 |
| Indicator | ETB | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | 35.00 | 48.78 |
| Support Level | $14.73 | $9.78 |
| Resistance Level | $15.04 | $12.56 |
| Average True Range (ATR) | 0.20 | 0.90 |
| MACD | -0.05 | -0.06 |
| Stochastic Oscillator | 0.74 | 30.44 |
Eaton Vance Tax-Managed Buy-Write Income Fund is a United States-based diversified closed ended management investment company. The fund's investment objective is to provide current income and gains, with a secondary objective of capital appreciation. It invests in a diversified portfolio of common stocks and writes call options on one or more U.S. indices on a substantial portion of the value of its common stock portfolio to generate current earnings from the option premium. Its portfolio of investments consists of aerospace and defense, banks, biotechnology, chemicals, consumer finance, industrial conglomerates, and others.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.